Martin-Luther-Universitaet Halle-Wittenberg

The department advances treatment for blood cancers, targeting acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma. Trials evaluate novel drug combinations, aim to increase event‑free survival, and seek deeper molecular remission.

• FLT3‑mutated AML with targeted inhibitors
• CLL treated with next‑generation BTK inhibitors
• Venetoclax‑azacitidine regimens in newly diagnosed AML
• Myelodysplastic syndromes and high‑risk MDS
• Myelofibrosis therapies including JAK‑inhibitors

Over 100 trials and 74 investigators make Martin‑Luther‑Universitaet Halle‑Wittenberg a central European hub for hematology research.

Research in this area focuses on aggressive and refractory lymphomas, such as diffuse large B‑cell lymphoma and primary CNS lymphoma. Studies test immunotherapy‑based combos and aim to improve progression‑free survival.

• CD20‑targeted antibodies with lenalidomide
• Bispecific antibodies in relapsed follicular lymphoma
• Novel agents for high‑risk DLBCL
• CNS‑directed regimens for primary CNS lymphoma
• EBV‑positive lymphoma therapies

The site’s expertise in hematologic oncology supports more than a dozen lymphoma trials, contributing to better outcomes for patients with rare CNS disease.

The clinic conducts studies on major solid cancers, including non‑small cell lung cancer, metastatic melanoma, and neuroendocrine tumors of the pancreas. Objectives range from evaluating targeted agents to improving disease control.

• Immunotherapy plus chemotherapy in NSCLC
• BRAF‑inhibitor combinations for advanced melanoma
• Ramucirumab with dacarbazine for pancreatic neuroendocrine tumors
• HER2‑positive esophagogastric adenocarcinoma trials
• Metastatic colorectal cancer maintenance strategies

With a strong multidisciplinary team, the site integrates surgical, radiologic, and medical expertise to accelerate therapeutic advances for solid tumors.

Clinical work includes allogeneic hematopoietic stem cell transplantation, management of graft‑versus‑host disease, and treatment of immune‑mediated conditions such as chronic urticaria. Trials assess conditioning regimens, novel prophylaxis, and targeted therapies.

• Non‑total body irradiation conditioning vs. TBI in pediatric HSCT
• Ravulizumab for post‑transplant thrombotic microangiopathy
• BMS‑986158 with ruxolitinib or fedratinib in myelofibrosis
• Apraglutide for steroid‑refractory gastrointestinal GvHD
• Selinexor‑ruxolitinib combination in treatment‑naïve myelofibrosis

The department’s transplant program, supported by 74 investigators, drives innovation in immune regulation and post‑transplant care.

Studies address childhood cancers such as acute lymphoblastic leukemia, neuroblastoma, and medulloblastoma. Research aims to refine risk‑adapted therapy, reduce toxicity, and improve long‑term survival.

• Ph+ ALL with imatinib versus intensified chemotherapy
• FLT3‑mutated pediatric AML with midostaurin
• High‑risk neuroblastoma consolidation strategies
• Hyperfractionated radiotherapy for high‑risk medulloblastoma
• Bortezomib‑enhanced consolidation in early‑high‑risk ALL

The site’s pediatric program contributes to international consortia, offering more than 20 trials focused on children and adolescents.

Research spans pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and metabolic disorders such as anemia in myelodysplastic syndromes. Trials test novel agents, assess safety, and explore disease‑modifying outcomes.

• Seralutinib long‑term safety in PAH
• Combination therapy for idiopathic pulmonary fibrosis
• Tranexamic acid to reduce bleeding in major abdominal surgery
• Nutritional interventions for anemia in low‑risk MDS
• Pulmonary hypertension associated with interstitial lung disease

The interdisciplinary unit leverages the site’s extensive trial portfolio to address cardiovascular and respiratory challenges in adult patients.